- 12Feb, 2026
February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]
Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance
Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.
Turning the Tide: Innovations in the Fight Against Super Gonorrhea
As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.
Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.
- 15Jul, 2025
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
- 15Jul, 2025
A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.
- 15Jul, 2025
TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.
